ALK and anaplastic large cell lymphoma: Indeed, it is likely that, together with the ongoing development of autophagy-modulating drugs [22,124,125,126], immune-checkpoint inhibitors [127,128], and ALK immunotherapies [107,108,129,130], this might lead in the near future to the better management of ALK+ ALCL patients.